source
- Pfizer signs $2.6 billion China deal to develop in-vivo CAR-T therapies for autoimmune diseasePfizer announced a collaboration with Chinese biotech Starna Therapeutics to pursue in-vivo CAR-T cell therapies aimed at autoimmune disorders. Under the agreement, Pfizer will receive exclusive r…
- AI bio startup Boltz secures $110 million Series A as AI drug design platform usage surgesBoltz, an artificial‑intelligence driven biotech startup, announced a $110 million Series A financing round less than a year after emerging from stealth with an initial $28 million investment. The…